MedTrace Logo

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-11-16

Study results available
· View outcomes & findings →

Summary

This trial is to assess the efficacy of pembrolizumab added to concurrent chemotherapy with or without radiation therapy in patients with small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

BIOLOGICAL

Pembrolizumab

200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.

DRUG

Cisplatin

75 mg/m2

DRUG

Carboplatin

AUC 6

DRUG

Etoposide

IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).

RADIATION

Radiation therapy

Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).

Sponsors & Collaborators

Principal Investigators

  • Joshua Sabari, MD, · NYU Perlmutter Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-23
Primary Completion
2019-10-01
Completion
2019-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02934503 on ClinicalTrials.gov